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Background: Cortisol binding globulin (CBG) is produced by
liver cells and is inhibited by proinflammatory cytokines such
as interleukin (IL) 6. CBG serum levels are typically low
during prolonged inflammatory processes. Thus, observed
changes of cortisol during anti-tumour necrosis factor (TNF)
treatment may be related to changes of CBG in rheumatoid
arthritis (RA).
Objective: To investigate the course of CBG during anti-TNF
treatment in RA.
Methods: 13 patients with longstanding RA, without prior
prednisolone treatment, were included in this longitudinal
study with subcutaneous adalimumab.
Results: Treatment with anti-TNF markedly decreased clinical
markers of inflammation and serum IL6. Serum levels of
cortisol, CBG, and the ratio of cortisol/CBG did not change
markedly, whereas the ratio of serum CBG/IL6 increased
(p = 0.004). In parallel, levels of adrenocorticotropic hor-
mone decreased during the observation period. The ratio
serum androstenedione/serum cortisol increased during the
study (p = 0.036).
Conclusions: During anti-TNF treatment relatively normal
levels of CBG and a normal ratio of CBG/cortisol are found.
Changes of cortisol in relation to IL6 during anti-TNF
treatment, seen previously, may not be related to changes
of CBG.
I
n a chronic inflammatory disease such as rheumatoid
arthritis (RA), the hypothalamic-pituitary-adrenal (HPA)
axis is altered: (a) patients have low spontaneous and
stimulated cortisol secretion in relation to inflammation1–7;
(b) secretion of adrenocorticotropic hormone (ACTH) relative
to inflammation is inadequate7; and (c) adrenal androgens
decrease.8–11 The causes of these alterations are only partly
understood, but striking changes on all levels of the HPA axis
seem to have a role. Cytokines such as interleukin (IL) 6 and
tumour necrosis factor (TNF) are likely to play a prominent
part in these alterations.
In a German RA cohort, we recently demonstrated that
long term treatment with the anti-TNF agent infliximab
sensitises the pituitary gland and favours adrenal androgen
secretion.12 Because production of cortisol binding globulin
(CBG) may be inhibited by proinflammatory cytokines such
as IL6,13 14 changes of cortisol, seen previously, may be
dependent on changes of CBG serum levels. The present
study in patients with RA receiving anti-TNF treatment
aimed at investigating serum levels of CBG. We used a
different cohort from Italy than in the earlier study12 and
used a different anti-TNF agent adalimumab (to demonstrate
possible class effects of anti-TNF antibodies).
PATIENTS AND METHODS
Patients and blood samples
In this study with adalimumab (Abbot SpA, Campoverde di
Aprilia, Italy), we included 13 white patients with RA (all
postmenopausal women) who fulfilled the American College
of Rheumatology criteria for RA.15 The patients were selected
according to the inclusion criteria of the Adalimumab
Research in Active RA study (ReAct). None of the patients
were receiving prednisolone or had received it previously
(6 months before). All patients were given additional
methotrexate (stable throughout this study) but no other
immunosuppressive drugs (table 1). Patients were assigned
to receive single self injections of adalimumab 40 mg
subcutaneously every other week. Efficacy assessments
included the American College of Rheumatology and
EULAR response criteria (FA, PS-P).16 A baseline blood
sample was taken 1–2 weeks before the start of the
Abbreviations: ACTH, adrenocorticotropic hormone; ASD,
androstenedione; CBG, cortisol binding globulin; HPA, hypothalamic-
pituitary-adrenal; IL, interleukin; RA, rheumatoid arthritis; TNF, tumour
necrosis factor
Table 1 Characteristics of the 13 female patients with
RA
Characteristics Patients with RA
Age (years) 58.2 (2.4) {48–73}
Disease duration (years) 6.5 (1.8) {0.5–20}
Baseline ESR (mm/ 1st h) 32.6 (5.5)
Baseline C reactive protein (mg/l) 143.4 (52.3)
Baseline serum IL6 (pg/ml) 23.2 (8.9)
Positive for rheumatoid factor, No (%) 13 (100)
Positive for antinuclear antibodies, No (%) 0 (0)
Baseline swollen joint score (points) 9.3 (0.6)
Baseline tender joint score (points) 10.9 (0.9)
Additional treatment
Prednisolone, No (%) 0 (0)
Methotrexate, No (%) 13 (100)
Mean weekly methotrexate (mg) 8.7 (0.9)
NSAID (COX-1, COX-2), No (%) 12 (92)
COX-2 inhibitors, No (%) 5 (38)
Azathioprine, No (%) 0 (0)
Leflunomide, No (%) 0 (0)
Chloroquine/hydroxychloroquine, No (%) 0 (0)
Ciclosporin A, No (%) 0 (0)
Sulfasalazine, No (%) 0 (0)
Data are given as mean (SEM) {range} unless stated otherwise.
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adalimumab treatment. Anti-TNF antibodies were infused on
weeks 0, 2, 4, 6, 8, 10, and 12. For this study, patients were
clinically investigated and blood was drawn between 8 00
and 9 00 am when the patients visited the outpatient clinic
on the baseline day or at weeks 2, 6, and 12. The blood was
immediately centrifuged and serum was stored at 280 C˚. The
study was approved by the ethics committee of L Sacco
University Hospital, Milan, Italy.
Laboratory variables
We used radioimmunometric assays for the quantitative
determination of serum levels of CBG (Biosource, Nivelles,
Belgium) and cortisol (Coulter Immunotech, Marseilles,
France). Serum levels of IL6 (high sensitivity Quantikine,
R&D Systems, Minneapolis, MN, USA), androstenedione
(ASD; IBL, Hamburg, Germany), and ACTH (Sangui BioTech,
Inc, California, USA) were measured by immunometric
enzyme immunoassays. Intra-assay and interassay coeffi-
cients of variation for all tests were ,10%.
Statistical analysis
Means between different time points during the course of
anti-TNF treatment were compared by Wilcoxon’s signed
rank test for paired data (SPSS/PC, Advanced Statistics,
version 11.5.1, SPSS Inc, Chicago). A decrease or increase of a
variable over time (during anti-TNF treatment) was tested by
the non-parametric Friedman test (SPSS). A value of p,0.05
was the significance level.
RESULTS
Anti-TNF treatment with adalimumab decreased the swollen
joint count (baseline v 12 weeks: 9.3 (0.6) v 2.9 (0.6),
p=0.001), tender joint count (10.9 (0.9) v 6.5 (0.4),
p=0.005), and serum levels of IL6 (23.2 (8.9) v 3.2 (1.0),
p=0.002).
Because cortisol determination may be influenced by
presence of serum CBG, we measured this particular
transport protein in this study. Baseline serum CBG was
normal, and serum CBG did not markedly change during the
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Figure 1 Course of serum cortisol binding globulin (CBG) and androstenedione (ASD) in relation to cortisol during 12 weeks of anti-TNF antibody
treatment in patients with RA. Baseline values are given as time point 0. The graph depicts serum CBG (A), the ratio serum cortisol/CBG (B), the ratio
serum CBG/IL6 (C), serum ASD (D), and the ratio serum ASD/cortisol (E). The data are given as means (SEM). The p value according to Friedman’s test
is given.
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treatment (fig 1A). Serum cortisol in relation to serum CBG
also did not change during anti-TNF treatment (fig 1B). The
ratio of serum CBG/IL6 significantly increased during the
observation period (fig 1C).
ASD is one of the major adrenal androgens. The ratio of
serum ASD/cortisol increased during the observation period,
which indicates that adrenal androgen secretion increases
relative to cortisol secretion (fig 1E).
In addition, levels of ACTH decreased during the 12 weeks
of anti-TNF treatment (baseline v 12 weeks: 1.6 (0.1) v 1.2
(0.1) pmol/l, p=0.007), but cortisol remained relatively
stable (615.3 (81.5) v 569.6 (77.1) nmol/l). We recently
demonstrated that levels of hormones in relation to serum
IL6 can be used to estimate HPA axis activity in relation to
this cytokine.7 This technique demonstrated that ACTH and
cortisol serum levels increased relative to serum levels of IL6
(ACTH/IL6: 0.46 (0.28) v 0.86 (0.24) (pmol/l)/(pg/ml);
cortisol/IL6: 62.1 (22.8) v 390.2 (108.1) (nmol/l)/(pg/ml)).
This indicates that the main hormones of the HPA axis
normalise relative to serum IL6. For ACTH and cortisol,
serum levels are respectively two and four times higher in
relation to IL6 at 12 weeks than at baseline.
DISCUSSION
CBG binds glucocorticoid hormones and regulates their
biological availability to target cells.17 CBG is mainly
produced by the liver in all species examined.18 IL6 and
other proinflammatory cytokines can decrease production of
CBG from liver cells.13 14 Thus, the proinflammatory load may
decrease CBG serum concentrations in RA, which has been
demonstrated in patients with prolonged critical illness in
intensive care units.19 In this study, CBG baseline levels were
normal in patients with RA. Furthermore, CBG serum levels
did not markedly change during the course of anti-TNF
treatment. In view of these findings, we suggest that
measurement of serum levels of cortisol are not markedly
influenced by CBG concentrations in patients with RA.
In addition to the marked improvement of clinical and
laboratory measures of inflammation, treatment with adali-
mumab decreased IL6 secretion. IL6 can be considered as a
hormone which informs the adrenal gland and the central
nervous system about the inflammatory status of peripheral
joints.20 It is important to mention that the hypothalamic-
pituitary axis, particularly, undergoes desensitisation upon
repetitive IL6 stimuli, with a marked unresponsiveness of
ACTH secretion.21 22 Removal of the IL6 proinflammatory load
by anti-TNF treatment leads to increased cortisol levels
relative to IL6. This phenomenon is probably not much
influenced by CBG because this transport protein remains
constant. This study also demonstrated that ACTH serum
levels decrease during anti-TNF treatment, which also shows
that the proinflammatory load stimulates ACTH secretion.
The improvement of the hypothalamic-pituitary function can
further be demonstrated when serum levels of ACTH are
expressed relative to IL6.
Earlier studies have shown that adrenal androgen secretion
is low in patients with RA.8–11 In our earlier study we
demonstrated relatively normal serum levels of ASD during
the course of anti-TNF treatment.12 This was confirmed in
this present study in Italian patients with RA treated with a
different anti-TNF antibody. The relative preponderance of
the glucocorticoid pathway (to cortisol) in relation to the
androgen pathway (to ASD) was seen when the ratio of
serum cortisol/ASD was used. This particular ratio increased
during anti-TNF treatment with infliximab,12 which was
confirmed in this present study with adalimumab. These
findings suggest that anti-TNF treatment favours ASD
secretion relative to cortisol.
In conclusion, our present anti-TNF study with adalimu-
mab in an Italian RA cohort demonstrated that CBG levels
are not markedly altered during anti-TNF treatment. Thus,
measurement of cortisol levels during anti-TNF treatment
relative to serum levels of IL6 is probably not influenced by
CBG levels. Furthermore, we confirmed some of our recent
findings in a German RA population using infliximab. Both
studies showed that the HPA axis relative to IL6 was
normalised and that adrenal androgens were increased
relative to cortisol. These positive effects must be considered
as an additional systemic anti-inflammatory influence of
anti-TNF treatment in patients with RA.
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